Verona Pharma 2022 - Ensifentrine COPD Therapy

Verona Pharma presents ensifentrine, a Phase 3 first-in-class dual PDE3/PDE4 inhibitor for maintenance treatment of COPD. The presentation outlines the ~$10.5B US market opportunity, significant unmet need with >1M symptomatic patients on dual/triple therapy, and the candidate's novel dual mechanism of action with demonstrated efficacy and safety profile.